GEN1E - this contract will provide support to GEN1E lifesciences INC. (GEN1E), a US company, for the advancement of patient stratification and endotyping approaches as IT develops GEN-1124, a novel…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00063
- Awardee
-
Gen1E Lifesciences Inc. UEI FTD3FAKEF2Z8
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,000
Award facts
- Contract value 100% obligated
- $749,000.00 Current and potential, with all options
- Completion date 73% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 100 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Palo Alto, CA 94306, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,000 |
About this award
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $749,000 firm fixed-price contract to Gen1E Lifesciences Inc. on September 22, 2023, for support in advancing patient stratification and endotyping approaches related to GEN-1124, a novel therapeutic candidate for acute respiratory distress syndrome (ARDS). The contract, which carries no set-aside designation, is structured as a definitive contract with a completion deadline of December 30, 2027. Work will be performed at the company's location in Palo Alto, California.
The contract supports an AI-powered endotyping study in Phase 2 clinical development of GEN-1124 for ARDS treatment. This engagement aligns with ASPR's broader mission to enhance medical countermeasures and preparedness capabilities, particularly for serious infectious diseases and respiratory conditions. By focusing on patient stratification and endotyping—approaches that identify patient subgroups likely to benefit from specific treatments—the contract aims to improve the precision and efficacy of this investigational therapy during its clinical development phase.
Description
GEN1E - this contract will provide support to GEN1E lifesciences INC. (GEN1E), a US company, for the advancement of patient stratification and endotyping approaches as IT develops GEN-1124, a novel treatment for acute respiratory distress syndrome (a
Quick answers
Who was awarded contract 75A50123C00063?
75A50123C00063 was awarded to Gen1E Lifesciences Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 22, 2023.
How much is contract 75A50123C00063 worth?
The government has obligated $749,000 on 75A50123C00063.
Was contract 75A50123C00063 competed?
The extent of competition for 75A50123C00063 was full and open competition. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award